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Abstract
Background: Head and neck cancers include malignancies of the mouth, larynx and oropharynx. Tobacco use and
alcohol consumption are associated with increased risks of developing and dying from head and neck cancer. The
aim of this review is to examine the effectiveness of smoking and alcohol cessation interventions on disease-related
outcomes, quality of life and behavioural change in adults with head and neck cancer and oral dysplasia.
Methods: The Cochrane library, CINAHL, Embase, MEDLINE, PsycINFO and Web of Science databases will be
searched for randomised controlled trials investigating the effects of smoking or alcohol interventions on patients
with either head and neck cancer or oral dysplasia. The primary outcomes are disease-free survival and, for
participants with oral dysplasia, malignant transformation to cancer. Secondary outcomes are disease recurrence
and progression, quality of life and behavioural change. The quality of included studies will be assessed using the
‘Cochrane Collaborations tool for assessing risk of bias’. A qualitative synthesis of the results will be reported, and a
meta-analysis of the outcome data conducted, where appropriate.
Discussion: This systematic review will identify the extent of the current research on smoking and alcohol
cessation interventions in patients with head and neck cancer and oral epithelial dysplasia. The findings have the
potential to inform which interventions have been successful and how future behavioural change interventions
should be conducted within these populations.
Systematic review registration: PROSPERO CRD42016038237
Keywords: Head and neck cancer, Oral dysplasia, Systematic review, Tobacco cessation, Alcohol
Background
Head and neck cancers are a heterogeneous group of ma-
lignancies which include cancers of the mouth, sinus, lar-
ynx, nasopharynx and oropharynx. The most common
type of head and neck cancer is squamous cell carcinoma
of the mucosal surfaces of the mouth, nose and throat [1]
which accounts for 90% of cancers of the head and neck
[2]. It is estimated that 11,152 new cases were diagnosed
in the UK in 2012 [3], with more than 550,000 cases diag-
nosed annually worldwide [4]. Incidence rates vary based
on cancer site and while rates of oral cavity and oropha-
ryngeal cancers have risen over recent years, the incidence
of laryngeal cancer rates has declined which may be re-
lated to the reduction in smoking rates [5]. European rela-
tive survival rates for head and neck cancer patients are
estimated at 72% at 1 year and 42% at 5 years [6]. Overall
5-year survival for head and neck cancer in the UK has
been estimated at 45%; however, rates also vary by cancer
site [7]. In England, between 2009 and 2013, 5-year sur-
vival rates were 65.6% in oropharyngeal cancer, 56.1% in
oral cavity cancer and 27.8% in hypopharyngeal cancer [8].
Oral epithelial dysplasia is a potentially pre-malignant
condition that can progress to squamous cell carcinoma.
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Reported rates of mutation to oral cancer vary based on
the degree of dysplasia (16% for sever dysplasia to <5%
for mild dysplasia) [9]. Leukoplakia and erythroplakia
are two of the most common clinical presentations in
which dysplasia is found and rates of dysplasia vary be-
tween these lesions [10]. It is estimated that 5% of
people with leukoplakia have dysplasia or cancerous cells
while up to 50% of people with erythroplakia will de-
velop cancer [11].
Tobacco use, which can include both smoking and
chewing tobacco, and alcohol consumption are esti-
mated to account for approximately 75% of cancers of
the oral cavity, pharynx and larynx [12, 13]. In a pooled
analysis [12] of 15 case control studies of cigarette
smoking amongst study participants who never drank al-
cohol, smoking was associated with an increased risk of
head and neck cancer (OR for ever versus never smok-
ing = 2.13, 95% CI = 1.52 to 2.98) and a dose-response
relationship was observed for the frequency and dur-
ation of cigarette smoking. The pooled analysis also re-
ported that at least three alcoholic drinks per day
amongst study participants who never smoked was asso-
ciated with a 2.04 increased risk of head and neck cancer
(95% CI = 1.29 to 3.21).
Conversely, the risk factors for oral dysplasia are not
well understood; although, there is also evidence of links
to tobacco use and alcohol consumption [14, 15].
As well as increasing risk of disease, there is also evi-
dence to suggest that smoking and alcohol use can influ-
ence treatment outcomes [16, 17]. Smokers may be less
likely to respond to treatment if they smoke, resulting in
a lower rate of survival [18], and are at greater risk of ex-
periencing treatment side effects [19], while patients
who continue to consume alcohol seem to have a higher
risk of recurrence and second primary tumours [20, 21].
No previous systematic reviews on smoking or alcohol
interventions in patients being treated for head and neck
cancer or oral dysplasia were identified through an initial
scope of the literature, highlighting a need for the syn-
thesis of intervention data in this area.
Research objective
To examine the effectiveness of smoking and alcohol
cessation interventions on disease-related outcomes,
quality of life and behavioural change in adults with
head and neck cancer and oral dysplasia.
Methods
This protocol has been reported in accordance with the
“Preferred Reporting Items for Systematic review and
Meta-Analysis Protocols (PRISMA-P) 2015 checklist”
[22]. A populated checklist for this review protocol has
been provided in Additional file 1.
Eligibility criteria
Study design
Randomised controlled trials will be included. Quasi-
randomised trials, those where randomisation is done on
the basis of a pseudo-randomised sequence [23], and ob-
servational studies will be excluded.
Participants
The participants include adult patients aged at least 18,
diagnosed with either oral dysplasia or head and neck
cancer. For the purpose of this review, head and neck
cancers that will be included are cancers of the oral cav-
ity, larynx, hypopharynx and oropharynx as these are as-
sociated with tobacco and alcohol use.
Intervention
Interventions that will be included in the review are as
follows:
(a) Tobacco use reduction or cessation
interventions—including both psychosocial and
pharmacological interventions.
(b) Alcohol use reduction or cessation
interventions—including both psychosocial and
pharmacological interventions.
Trials that include a combination of these interven-
tions will also be included.
Comparison
We will include placebo or standard care as the com-
parison group, depending on intervention type (pharma-
cological or behavioural). Studies that compare multiple
active intervention arms but do not include a control
arm will also be included.
Outcomes
Studies will be included in the data extraction if they re-
port on one of the following primary or secondary
outcomes.
Primary outcomes
1. Disease-free survival: defined as the length of time
following treatment that the participant lived
without recurrence or relapse of the disease.
2. Malignant transformation in participants with oral
dysplasia: defined as the development of oral or
laryngeal cancer.
Secondary outcomes
1. Disease recurrence: defined as the return of the
cancer to the same primary site following treatment.
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2. Disease progression in people with head and neck
cancer: defined as the development or progression of
lymph node metastasis, the development of distant
metastasis or an increase in the size of the primary
tumour.
3. Quality of life measured by any standardised scale:
For example, including but not limited to the
European Organisation for Research and Treatment
of Cancer scales (including the head and neck
specific scale “QLQ-H&N35”), Functional
Assessment of Chronic Illness Therapy
Measurement Systems, Short Form Health
survey—SF36/SF12.
4. Adverse events related to the interventions. These
could include but are not limited to nicotine/alcohol
withdrawal related adverse events and adverse
events related to nicotine replacement therapy.
5. Behavioural change: defined as the proportion of
participants who successfully altered the behaviour
of interest, measured through either self-report or
biomarker methods.
6. Second primary cancers if they originated at least
3 cm away from the primary site and occurred at
least 3 years after the last known recurrence
7. Head and neck cancer specific mortality
8. All-cause mortality
Search strategy
Electronic searches
Literature searches will be performed in the following
databases for relevant published articles:
1. Cochrane library (from inception to present)
2. PsycINFO (from 1806 to present)
3. CINAHL (from 1937 to present)
4. Embase (from 1974 to present)
5. MEDLINE (from 1946 to present)
6. Web of Science (from 1900 to present)
An example of the search strategy for use in MED-
LINE is shown in Additional file 2. The same search
terms will be used for each database with any changes
made to the syntax as per individual database require-
ments. The searches will not be limited by date range or
language of publication. Searches performed in Web of
Science will enable conference abstracts to be yielded.
Searching other resources
Any systematic reviews found will be used to identify
further studies not found in the original search. The ref-
erence lists of all included articles will be hand searched
for additional studies. The search will be complemented
by contacting subject experts about any unpublished or
published studies that were not yielded from the original
search. The NIHR Clinical Trials gateway will also be
searched to identify any trials currently taking place
which have not yet reached publication stage [24] and
the first 20 pages of google scholar will be hand searched
for any additional articles.
Data management
Endnote reference management software will be used to
manage the search results. Database search results will
be imported into an Endnote library and duplicates re-
moved during the data screening process. All references
to the same study will be extracted and referred to in
the text of the main report.
Selection of studies
Studies for inclusion will be screened independently by
two reviewers (ES, LR). Initial screening will be performed
by both reviewers and compared to ensure accuracy. Any
discrepancies found will be discussed with a third reviewer
(RP) for resolution. Abstracts meeting the inclusion cri-
teria will be retrieved in full for data extraction.
Data extraction
Data will be extracted by two reviewers independently,
then compared for accuracy. Extraction will take place
using a standardised template designed specifically for
this review. This template will be piloted by both re-
viewers on the first five papers extracted, then discussed
to ensure common use and to agree on any amendments
required. Data will be extracted on the following:
a) Publication information—paper title, author details,
publication type, funding sources, year of study
b) Sample characteristics—number of participants,
demographics (age, sex, ethnicity), cancer site and
staging, inclusion/exclusion criteria, sub groups
included, withdrawals and exclusions
c) Intervention type and design—study design,
intervention description (including type, dose and
duration), method of randomisation. Timing of the
intervention (e.g. pre or post treatment) will also be
extracted.
d) Results—outcomes of interest reported (as defined
in the methods section of this protocol), statistical
methods used, summary statistics, means and
standard deviations or medians and inter quartile
ranges as appropriate, QOL scales used and resulting
QOL scores, adverse events.
e) Measures of methodological quality—detail provided
below under assessment of risk of bias.
Any discrepancies found will be discussed with a third
reviewer in order to finalise inclusion/exclusion.
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Assessment of risk of bias
Risk of bias and overall methodological quality will be
assessed by two reviewers independently using a table
based on the Cochrane Collaboration’s tool for assessing
risk of bias, which has been updated to reflect the
current study’s review parameters [25]. A copy of the
table of assessment criteria used for this study can be
seen in Table 1. Studies will be classified as having a low,
high or unclear risk of bias based on six criteria:
 Sequence generation
 Allocation concealment
 Blinding of participants, personnel and outcome
assessors (where practical and applicable)
 Incomplete outcome data
 Selective outcome reporting
 Other potential threats to validity, e.g. differences in
baseline characteristics between intervention groups
and conflict of interest of researchers.
Dealing with missing data
Study authors will be approached for any missing or
unreported data, as required. For the purposes of
meta-analyses where missing data are still present, we
will attempt to estimate these values from other re-
sults reported in the paper (e.g. if t values from t
tests are reported but no standard deviations, we can
calculate the standard deviations), or impute possible
values using the largest values from those studies
which did report the missing result (see “Sub-group
and sensitivity analyses” for further details).
Data analysis
We will undertake a qualitative synthesis of all stud-
ies. Due to the diverse nature of the interventions of
interest, we anticipate heterogeneity between studies
and will therefore use random effects models to
quantitatively synthesise all data relating to each com-
bination of intervention type and outcome measure.
For binary outcome measures (disease-free survival,
progression and recurrence, cancer specific and all-
cause mortality, and second primary cancers), we will
pool risk ratios and will calculate or estimate risk ra-
tios where possible from studies which do not report
them. Where hazard ratios are reported, we will pool
these separately and we will estimate hazard ratios
from studies which report suitable outcome measures
(e.g. median survival time for intervention and con-
trol arms). For continuous outcomes (quality of life),
we will pool means and associated standard deviations
and we will estimate mean and standard deviation
values where possible (e.g. median quality of life for
intervention and control arms). We will assess statis-
tical heterogeneity by visually inspecting forest plots
and with the chi-square measurement, with a cutoff
of P < 0.01 for the chi-square measurement to indi-
cate heterogeneity since it is difficult to assess when
sample sizes are small. We will use the I2 statistic to
Table 1 Risk of bias assessment table for the systematic review of smoking and alcohol interventions in head and neck cancer
Domain Low risk High risk
Sequence generation Describes a random component, e.g. random number
generator, coin toss and shuffling envelopes.
Includes a systematic, non-random component, e.g. hospital
record number, DOB, participant preference and based on
lab results.
Allocation concealment Participants/investigators could not foresee allocation, e.g.
central allocation system (web or phone based), sequentially
numbered supplement/placebo containers and sequentially
numbered sealed envelopes.
Participants/investigators could foresee allocation, e.g. an
open random allocation schedule, DOB, case record
numbers or assignment envelopes without appropriate
safeguards.
Blinding of participants,
personnel and outcome
assessors
No blinding conducted but this is deemed not likely to
outcome or outcome measurement.
No blinding but this is deemed either not appropriate or
possible, e.g. not blinding participants in PA or non-
supplement-based dietary intervention.
Blinding of participants and study personnel where
appropriate
No/incomplete blinding where the outcome measurement
is likely to have been affected.
Blinding conducted but likely that the blinding could have
been broken.
Incomplete outcome
data
Reason for missing outcome data unlikely to be related to
true outcome.
If participants are reported and analysed in the groups they
were allocated to irrespective of non-compliance/drop out.
Up to 10% loss through drop out or loss-to follow-up.
Reason for missing outcome data likely to be related to
true outcome.
Participants are not analysed based on the group they were
allocated.
Selective outcome
reporting
If all pre-specified outcomes have been reported on. Reporting on outcomes that were not pre-specified.
Outcomes of interest are reported incompletely
Fails to include results for an expected key outcome.
Other sources of bias The study appears to be free of any other sources of bias. Other possible cause of bias, e.g. extreme baseline
imbalance, claim of fraudulence and conflict of interest for
investigators not addressed.
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measure variation in the effect size due to heterogen-
eity, with values greater than 50% indicative of signifi-
cant heterogeneity [19]. If the studies are considered
too heterogeneous with regards to the intervention
design or outcome measure used, we will not pool
their effect sizes. We will test the likelihood of publi-
cation bias through visual inspection of funnel plots
and using Egger’s regression test.
If a meta-analysis is undertaken, the strength of the
body of evidence will be assessed using the GRADE
system [23].
Interventions which include a behavioural change
technique will also be coded for qualitative analysis
using the BCT Taxonomy (v1) to allow for compari-
son of techniques employed for the intervention [26].
Sub-group and sensitivity analyses
Where possible, we will analyse intervention effects
on primary and secondary outcomes within the fol-
lowing sub-groups: oral dysplasia compared with head
and neck cancer and between tumour sites. To min-
imise the impact of studies at high risk of bias, we
will exclude these and repeat our meta-analyses. Im-
putation of missing values using the largest reported
value from other studies can potentially bias results
towards a lack of effect [23], and therefore, as sensi-
tivity analyses to explore the impact of this imput-
ation method on our findings, we will repeat our
meta-analyses with two modifications. Firstly, instead
of replacing missing values with the largest reported
values, we used the mean of the reported values.
Secondly, studies which were missing data were
excluded.
Discussion
Due to evidence from observational studies that sug-
gests that those who reduce tobacco and alcohol con-
sumption have better outcomes, lifestyle interventions
aimed at cessation are of current interest. However,
to our knowledge, no systematic review has been
published to date that identifies the interventions
tested or how successful they have been at improving
clinical outcomes and quality of life. We anticipate
that this review will therefore inform the design and
conduct of further behavioural change interventions
in this population group.
This systematic review will identify the extent of
the current research on smoking and alcohol cessa-
tion interventions in patients with head and neck
cancer and oral dysplasia. Through review of the
current evidence, the findings will inform further re-
search into interventions aimed at improving out-
comes and quality of life in this patient group.
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